Adaptin Bio, Inc. Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs
Adaptin Bio, Inc. (APTN) had Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs of $31.00 million as of 2025-09-30, per its 10-Q filed 2025-11-14.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities
us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedResearchAndDevelopmentCosts · last filed 2025-11-14
- 2025-09-30: Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs $31.00M.
| Period end | Deferred Tax Liabilities, Deferred Expense, Capitalized Research and Development Costs |
|---|---|
| 2025-09-30 | $31.00M 10-Q · filed 2025-11-14 |